Evidence map›Paper›PMID 31939112›Full record

ArticleApplied health economics and health policy2020

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Renée Else Michels, Maria De Francesco, Koshu Mahajan, Gerald J D Hengstman, Krijn M H Schiffers, Sangeeta Budhia, Gerard Harty, Marieke Krol

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied health economics and health policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Renée Else MichelsIQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
Maria De FrancescoIQVIA, Real World Insights, Da Vincilaan 7, 1930, Zaventem, Belgium.
Koshu MahajanIQVIA, Real World Insights, Gurgaon, India.
Gerald J D HengstmanDepartment of Neurology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Krijn M H SchiffersMerck B.V., Tupolevlaan 41-61, 1119 NW, Schiphol-Rijk, The Netherlands.
Sangeeta BudhiaPAREXEL International, PAREXEL Access Consulting, London, UK.
Gerard HartyEMD Serono, a business of Merck KGaA, Boston, MA, USA.
Marieke KrolIQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. Marieke.Krol@iqvia.com.ORCID http://orcid.org/0000-0002-6153-0828

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The second author's name should be "Maria De Francesco" rather than "Maria de Fransesco".

Identifiers

PMID31939112
PMCPMC6978442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.